IVZ Form 4: Senior Managing Director Disposes 103,192 Shares at $22.12
Rhea-AI Filing Summary
Insider sale disclosed: Stephanie Butcher, Senior Managing Director and officer of Invesco Ltd. (IVZ), reported selling 103,192 common shares on 09/10/2025 at a weighted-average price of $22.121 per share, with reported sale prices ranging from $22.055 to $22.155. After the sale she beneficially owns 29,855 shares. The Form 4 was signed by an attorney-in-fact on 09/12/2025 and includes an offer to provide the breakdown of shares sold at each price upon request. The filing indicates these were non-derivative dispositions and does not state a plan or reason for the sales.
Positive
- Timely and complete disclosure of a material insider sale via Form 4
- Weighted-average price and price range provided, with an offer to furnish per-transaction details on request
Negative
- Large disposition of 103,192 shares on 09/10/2025, which could be viewed negatively without stated context
- No disclosure of a trading plan or reason for sale, limiting investors' ability to assess intent
Insights
TL;DR: Officer sold a large block of shares but retained a stake; filing is routine disclosure under Section 16.
The sale of 103,192 common shares by a senior managing director is a material insider disposition that must be transparently reported, which the filer fulfilled. The filing shows direct, non-derivative sales at a weighted-average price and discloses remaining beneficial ownership. The Form 4 contains an explicit offer to provide detailed per-transaction prices, which supports transparency. No information about a trading plan or reasons for the sale is provided, limiting governance context.
TL;DR: Significant share sale executed; impact depends on relative size versus total insider holdings and company float.
The transaction is recorded as multiple non-derivative sales executed on a single date at prices between $22.055 and $22.155, producing a weighted-average of $22.121. Post-sale beneficial ownership is 29,855 shares. The filing supplies concrete price and quantity data enabling calculation of gross proceeds (approximately $2.28 million based on weighted-average price), but it lacks context such as percent of total holdings or linkage to a 10b5-1 plan, so market-impact interpretation is limited.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Shares | 103,192 | $22.121 | $2.28M |
Footnotes (1)
- F1. Reflects the weighted-average sales price. Common Shares were sold in multiple transactions at prices ranging from $22.055 to $22.155 per share. The reporting person undertakes to provide upon request to the SEC staff, the issuer or its shareowners full information regarding the number of shares sold at each separate price.
FAQ
What did Stephanie Butcher report on Form 4 for IVZ?
Was the sale reported as part of a 10b5-1 trading plan?
Who signed the Form 4 filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.